Liraglutide Hospital Discharge Trial
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Liraglutide + OADs
Glargine + OADs
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Incretins, Liraglutide, Glargine, Randomized controlled trial, basal insulin, hospital discharge, inpatient diabetes
Eligibility Criteria
Inclusion Criteria:
- Males or females between the ages of 18 and 80 years discharged after hospital admission from non- ICU general surgery and medicine services (excluding gastrointestinal and cardiac surgeries).
- Admission HbA1c between 7% and 10%
- Patients with T2D treated with diet alone or with oral antidiabetic agents as monotherapy or in combination therapy (excluding GLP1 receptor agonists) or on low-dose insulin therapy (TDD ≤0.4 unit/kg/day) prior to admission.
- Subjects with a hospital admission BG < 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 mEq/L or positive serum or urinary ketones).
- BMI > 25 Kg/m2 and ≤ 45 Kg/m2
Exclusion Criteria:
- Age < 18 or > 80 years.
- Subjects with stress hyperglycemia (BG > 140 mg/dL and HbA1c < 6.5%)
- Subjects with a history of type 1 diabetes
- Treatment with insulin or GLP-1 analogs during the past 3 months prior to admission.
- Recurrent severe hypoglycemia or hypoglycemic unawareness.
- Subjects with gastrointestinal obstruction, gastroparesis, or those expected to require gastrointestinal suction.
- History of medullary thyroid cancer or multiple endocrine neoplasias
- Patients with acute or chronic pancreatitis, pancreatic cancer, or gallbladder disease.
- Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease, portal hypertension) and elevated ALT and AST > 3 times upper limit of normal, or significantly impaired renal function (GFR < 30 ml/min).
- Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone 5mg/day), parenteral nutrition, and immunosuppressive treatment.
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- Female subjects who are pregnant or breastfeeding at the time of enrollment into the study.
- Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice).
Sites / Locations
- University of Miami
- Grady Memorial Hospital
- Emory University Hospital
- Emory Universtiy Hospital at MIdtown
- State University of NY at Buffalo
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Liraglutide + OADs
Glargine + OADs
Arm Description
Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
Glargine once daily in combination to oral anti-diabetic agents (OADs)
Outcomes
Primary Outcome Measures
Glycemic Control at Hospital Discharge and 6 Months Follow up
To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy
Secondary Outcome Measures
Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks
To determine differences in BG concentration between liraglutide and glargine insulin therapy
Hypoglycemic Episodes
Number of participants who had at least one hypoglycemic event (<70 mg/dl) and severe hypoglycemic event (<40 mg/dl)
HbA1c <7.0% and no Hypoglycemia
Percent of patients with 26 week HbA1c <7.0% and no hypoglycemia
HbA1c <7.0% and no Weight Gain
Percent of patients with 26 week HbA1c <7.0% and no weight gain
HbA1c <7.0% and no Hypoglycemia
Percent of patients with 12 week HbA1c <7.0% and no hypoglycemia
Change in Body Weight From Baseline
Change in body weight from baseline after 6 months of follow up (26 weeks)
Change in BMI
Change in BMI after 6 months from baseline
Total Daily Dose of Insulin
Evaluate the total daily dose of insulin needed in the group receiving glargine
Change in Cardiovascular Risk Factors: Blood Pressure
Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention
Cardiovascular Risk Factor: Heart Rate
Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention
Cardiovascular Risk Factor: Lipid Profile
Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.
Emergency Room Visits and Readmissions
Number of participants who had at least one emergency room visit and hospital readmissions
Acute Renal Failure
Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine > 0.5 mg/dL from baseline)
Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up
Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up
Full Information
NCT ID
NCT01919489
First Posted
July 30, 2013
Last Updated
October 5, 2021
Sponsor
Emory University
Collaborators
Novo Nordisk A/S
1. Study Identification
Unique Protocol Identification Number
NCT01919489
Brief Title
Liraglutide Hospital Discharge Trial
Official Title
A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
March 2014 (Actual)
Primary Completion Date
August 30, 2020 (Actual)
Study Completion Date
August 30, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University
Collaborators
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. Increasing evidence indicates that incretin-based agents are safe and effective for the hospital management of patients with type 2 diabetes (T2D).
Liraglutide is a once-daily human glucagon-like peptide (GLP-1) analogue approved for the treatment of T2D. Liraglutide has been shown to lower blood glucose, stimulate endogenous insulin secretion, decrease plasma glucagon levels, inhibit gastric emptying, reduce food intake and body weight and improve ß-cell function when administered subcutaneously. Liraglutide increases insulin secretion in a glucose-dependent manner (i.e., only when plasma glucose levels are elevated), resulting in low-risk of hypoglycemia when used as monotherapy. When compared to insulin glargine therapy, the use of GLP-1 has resulted in comparable reduction in HbA1c level, lower rates of hypoglycemia and less weight gain. No prospective studies; however, have compared the efficacy and safety of liraglutide in the hospital setting or after hospital discharge.
The primary objective is to compare the safety and efficacy of liraglutide (Victoza®) versus glargine insulin in combination to oral anti-diabetic agents (OADs: metformin, sulfonylureas, nateglinide, repaglinide or pioglitazone) on glycemic control after 26 weeks of treatment in medicine patients with T2D after hospital discharge.
Detailed Description
Specific Aim: To determine whether treatment with liraglutide (Victoza®) will result in similar glycemic control (HbA1c at 26 weeks) and a lower rate of hypoglycemic events compared to treatment with glargine (Lantus®) in patients with T2D after hospital discharge. Patients with poorly controlled (HbA1c >7%-10%) T2D treated with diet or oral antidiabetic agents or low dose insulin naïve (0.4u/kg/day) prior to admission will be randomized to liraglutide or glargine in combination to OADs at hospital discharge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Incretins, Liraglutide, Glargine, Randomized controlled trial, basal insulin, hospital discharge, inpatient diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
273 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Liraglutide + OADs
Arm Type
Experimental
Arm Description
Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
Arm Title
Glargine + OADs
Arm Type
Active Comparator
Arm Description
Glargine once daily in combination to oral anti-diabetic agents (OADs)
Intervention Type
Drug
Intervention Name(s)
Liraglutide + OADs
Other Intervention Name(s)
Victoza® + OADs
Intervention Description
Liraglutide subcutaneously daily
Intervention Type
Drug
Intervention Name(s)
Glargine + OADs
Other Intervention Name(s)
Glargine (Lantus®) + OADs
Intervention Description
Glargine once daily subcutaneously
Primary Outcome Measure Information:
Title
Glycemic Control at Hospital Discharge and 6 Months Follow up
Description
To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy
Time Frame
Hospital discharge, 6 months (26 weeks)
Secondary Outcome Measure Information:
Title
Fasting and Postprandial Blood Glucose (BG) Concentration After Follow up of 26 Weeks
Description
To determine differences in BG concentration between liraglutide and glargine insulin therapy
Time Frame
After discharge, average at 3 months (12 week) and 6 months (26 weeks)
Title
Hypoglycemic Episodes
Description
Number of participants who had at least one hypoglycemic event (<70 mg/dl) and severe hypoglycemic event (<40 mg/dl)
Time Frame
After discharge, average 6 months
Title
HbA1c <7.0% and no Hypoglycemia
Description
Percent of patients with 26 week HbA1c <7.0% and no hypoglycemia
Time Frame
After discharge, average 6 months
Title
HbA1c <7.0% and no Weight Gain
Description
Percent of patients with 26 week HbA1c <7.0% and no weight gain
Time Frame
After discharge, average 6 months
Title
HbA1c <7.0% and no Hypoglycemia
Description
Percent of patients with 12 week HbA1c <7.0% and no hypoglycemia
Time Frame
After discharge, average 12 weeks
Title
Change in Body Weight From Baseline
Description
Change in body weight from baseline after 6 months of follow up (26 weeks)
Time Frame
After discharge, average 6 months
Title
Change in BMI
Description
Change in BMI after 6 months from baseline
Time Frame
Baseline, and follow up after discharge (average 6 months)
Title
Total Daily Dose of Insulin
Description
Evaluate the total daily dose of insulin needed in the group receiving glargine
Time Frame
After discharge, average 6 months
Title
Change in Cardiovascular Risk Factors: Blood Pressure
Description
Cardiovascular risk factors including changes in systolic and diastolic blood pressure from baseline to 26 weeks post-intervention
Time Frame
Baseline, 26 weeks post-intervention
Title
Cardiovascular Risk Factor: Heart Rate
Description
Cardiovascular risk: heart rate at baseline and 26 weeks post-intervention
Time Frame
26 weeks post-intervention
Title
Cardiovascular Risk Factor: Lipid Profile
Description
Lipid profile was measured with total cholesterol level results at 26 weeks post-intervention. This outcome was not part of standard of care.
Time Frame
26 weeks post-intervention
Title
Emergency Room Visits and Readmissions
Description
Number of participants who had at least one emergency room visit and hospital readmissions
Time Frame
After discharge, average 6 months
Title
Acute Renal Failure
Description
Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine > 0.5 mg/dL from baseline)
Time Frame
After discharge, average 6 months
Title
Self-measured Blood Glucose (SMBG) 7-point Profiles at 26 Weeks Follow up
Description
Number of participants that reported self-measured blood glucose (SMBG) 7-point profiles at 26 weeks follow up
Time Frame
26 weeks post-intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males or females between the ages of 18 and 80 years discharged after hospital admission from non- ICU general surgery and medicine services (excluding gastrointestinal and cardiac surgeries).
Admission HbA1c between 7% and 10%
Patients with T2D treated with diet alone or with oral antidiabetic agents as monotherapy or in combination therapy (excluding GLP1 receptor agonists) or on low-dose insulin therapy (TDD ≤0.4 unit/kg/day) prior to admission.
Subjects with a hospital admission BG < 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 mEq/L or positive serum or urinary ketones).
BMI > 25 Kg/m2 and ≤ 45 Kg/m2
Exclusion Criteria:
Age < 18 or > 80 years.
Subjects with stress hyperglycemia (BG > 140 mg/dL and HbA1c < 6.5%)
Subjects with a history of type 1 diabetes
Treatment with insulin or GLP-1 analogs during the past 3 months prior to admission.
Recurrent severe hypoglycemia or hypoglycemic unawareness.
Subjects with gastrointestinal obstruction, gastroparesis, or those expected to require gastrointestinal suction.
History of medullary thyroid cancer or multiple endocrine neoplasias
Patients with acute or chronic pancreatitis, pancreatic cancer, or gallbladder disease.
Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease, portal hypertension) and elevated ALT and AST > 3 times upper limit of normal, or significantly impaired renal function (GFR < 30 ml/min).
Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone 5mg/day), parenteral nutrition, and immunosuppressive treatment.
Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
Female subjects who are pregnant or breastfeeding at the time of enrollment into the study.
Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillermo E Umpierrez, MD
Organizational Affiliation
Emory University SOM
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Miami
City
Miami
State/Province
Florida
Country
United States
Facility Name
Grady Memorial Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States
Facility Name
Emory University Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30324
Country
United States
Facility Name
Emory Universtiy Hospital at MIdtown
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
State University of NY at Buffalo
City
New York
State/Province
New York
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Liraglutide Hospital Discharge Trial
We'll reach out to this number within 24 hrs